MA38482B1 - Dérivés de pyridin-4-yle agonistes du recepteur de la sphingosine-1-phosphate utilises pour traiter, par ex. Syndromes auto-immuns, sclerose en plaques, colite ulcereuse, psoriasis et migraine - Google Patents

Dérivés de pyridin-4-yle agonistes du recepteur de la sphingosine-1-phosphate utilises pour traiter, par ex. Syndromes auto-immuns, sclerose en plaques, colite ulcereuse, psoriasis et migraine

Info

Publication number
MA38482B1
MA38482B1 MA38482A MA38482A MA38482B1 MA 38482 B1 MA38482 B1 MA 38482B1 MA 38482 A MA38482 A MA 38482A MA 38482 A MA38482 A MA 38482A MA 38482 B1 MA38482 B1 MA 38482B1
Authority
MA
Morocco
Prior art keywords
sphingosine
migraine
pyridin
psoriasis
agonists
Prior art date
Application number
MA38482A
Other languages
English (en)
Other versions
MA38482A1 (fr
Inventor
Martin Bolli
Cyrille Lescop
Oliver Nayler
Beat Steiner
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of MA38482A1 publication Critical patent/MA38482A1/fr
Publication of MA38482B1 publication Critical patent/MA38482B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Cette invention concerne des composés de formule (i), formule (i) dans laquelle r1et r2 sont tels que définis dans la description, leur préparation et leur utilisation à titre de composés pharmaceutiquement actifs, lesdits composés agissant en particulier comme des agents immunomodulateurs.
MA38482A 2013-03-15 2014-03-14 Dérivés de pyridin-4-yle agonistes du recepteur de la sphingosine-1-phosphate utilises pour traiter, par ex. Syndromes auto-immuns, sclerose en plaques, colite ulcereuse, psoriasis et migraine MA38482B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13159482 2013-03-15
PCT/IB2014/059794 WO2014141171A1 (fr) 2013-03-15 2014-03-14 Dérivés de pyridin-4-yle

Publications (2)

Publication Number Publication Date
MA38482A1 MA38482A1 (fr) 2017-12-29
MA38482B1 true MA38482B1 (fr) 2018-11-30

Family

ID=47877933

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38482A MA38482B1 (fr) 2013-03-15 2014-03-14 Dérivés de pyridin-4-yle agonistes du recepteur de la sphingosine-1-phosphate utilises pour traiter, par ex. Syndromes auto-immuns, sclerose en plaques, colite ulcereuse, psoriasis et migraine

Country Status (34)

Country Link
US (1) US9617250B2 (fr)
EP (1) EP2970236B1 (fr)
JP (1) JP6387361B2 (fr)
KR (1) KR102212975B1 (fr)
CN (1) CN105189487B (fr)
AR (1) AR095523A1 (fr)
AU (1) AU2014229217B2 (fr)
BR (1) BR112015023161B1 (fr)
CA (1) CA2900910C (fr)
CL (1) CL2015002620A1 (fr)
CY (1) CY1119619T1 (fr)
DK (1) DK2970236T3 (fr)
EA (1) EA029309B1 (fr)
ES (1) ES2649475T3 (fr)
HK (1) HK1220454A1 (fr)
HR (1) HRP20171763T1 (fr)
HU (1) HUE035154T2 (fr)
IL (1) IL241363B (fr)
LT (1) LT2970236T (fr)
MA (1) MA38482B1 (fr)
MX (1) MX363545B (fr)
MY (1) MY173573A (fr)
NO (1) NO2970236T3 (fr)
NZ (1) NZ713080A (fr)
PH (1) PH12015502118B1 (fr)
PL (1) PL2970236T3 (fr)
PT (1) PT2970236T (fr)
SA (1) SA515361104B1 (fr)
SG (1) SG11201507227UA (fr)
SI (1) SI2970236T1 (fr)
TW (1) TWI623534B (fr)
UA (1) UA115357C2 (fr)
WO (1) WO2014141171A1 (fr)
ZA (1) ZA201507657B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014110574A1 (fr) 2013-01-14 2014-07-17 Incyte Corporation Composés de carboxamide aromatique bicyclique utiles comme inhibiteurs de pim kinase
ME03780B (fr) 2013-01-15 2021-04-20 Incyte Holdings Corp Dérivés de thiazolecarboxamide et pyridinecarboxamide et leur utilisation comme inhibiteurs des kinases pim
PE20160532A1 (es) 2013-08-23 2016-05-21 Incyte Corp Compuesto de carboxamida de furo y tienopiridina utiles como inhibidores de cinasas pim
WO2016010897A1 (fr) 2014-07-14 2016-01-21 Incyte Corporation Composés carboxamide hétéroaromatiques bicycliques utiles en tant qu'inhibiteurs de kinases pim
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
HUE047646T2 (hu) 2015-05-20 2020-05-28 Idorsia Pharmaceuticals Ltd Az (S)-3-{4-[5-(2-ciklopentil-6-metoxi-piridin-4-il)-[1,2,4]oxadiazol-3-il]-2-etil-6-metil-fenoxi} -propán-1,2-diol vegyület kristályformája
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
WO2017004610A1 (fr) * 2015-07-02 2017-01-05 Exelixis, Inc. Agonistes de récepteur s1p1 économisant le s1p3 tercyclique
TWI734699B (zh) 2015-09-09 2021-08-01 美商英塞特公司 Ｐｉｍ激酶抑制劑之鹽
TW201718546A (zh) 2015-10-02 2017-06-01 英塞特公司 適用作pim激酶抑制劑之雜環化合物
WO2019113487A1 (fr) 2017-12-08 2019-06-13 Incyte Corporation Polythérapie à faible dose pour le traitement de néoplasmes myéloprolifératifs

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7686891A (en) 1990-04-05 1991-10-30 American National Red Cross, The A protein family related to immediate-early protein expressed by human endothelial cells during differentiation
US6423508B1 (en) 1998-03-09 2002-07-23 Smithkline Beecham Corporation Polynucleotide sequences of human EDG-1c
WO2004035538A1 (fr) 2002-10-15 2004-04-29 Merck & Co., Inc. Procede de fabrication de l'acide azetidine-3-carboxylique
TWI392671B (zh) 2006-09-07 2013-04-11 Actelion Pharmaceuticals Ltd 吡啶-４-基衍生物
PL2069335T3 (pl) 2006-09-08 2013-05-31 Actelion Pharmaceuticals Ltd Pochodne pirydyn-3-ylu jako środki immunomodulujące
ES2393412T3 (es) 2006-09-21 2012-12-21 Actelion Pharmaceuticals Ltd. Derivados de fenilo y su uso como inmunomoduladores
DK2125797T3 (da) 2007-03-16 2014-02-10 Actelion Pharmaceuticals Ltd Aminopyridinderivater som s1p1/edg1-receptoragonister
WO2009024905A1 (fr) 2007-08-17 2009-02-26 Actelion Pharmaceuticals Ltd Dérivés pyridiniques utilisés comme modulateurs du récepteur s1p1/edg1
EA201070422A1 (ru) 2007-10-04 2010-12-30 Мерк Сероно С.А. Производные оксадиазола
AU2008320374A1 (en) 2007-11-01 2009-05-07 Actelion Pharmaceuticals Ltd Novel pyrimidine derivatives
WO2009109907A1 (fr) 2008-03-06 2009-09-11 Actelion Pharmaceuticals Ltd Nouveaux dérivés de pyrimidine-pyridine
JP5411877B2 (ja) 2008-03-06 2014-02-12 アクテリオン ファーマシューティカルズ リミテッド ピリジン化合物
EP2262782B1 (fr) 2008-03-07 2012-07-04 Actelion Pharmaceuticals Ltd. Nouveaux dérivés d'aminométhylbenzène
KR101615779B1 (ko) 2008-03-07 2016-04-26 액테리온 파마슈티칼 리미티드 면역조절제로서 피리딘-2-일 유도체
PT2291080E (pt) * 2008-05-14 2015-10-30 Scripps Research Inst Novos modelamodeladores dos recetores da esfingosina fosfato
ES2517265T3 (es) 2009-03-03 2014-11-03 Merck Serono S.A. Derivados de oxadiazol piridina
RU2547098C2 (ru) 2009-07-16 2015-04-10 Актелион Фармасьютиклз Лтд Производные пиридин-4-ила
TW201120016A (en) 2009-12-08 2011-06-16 Abbott Lab Novel oxadiazole compounds
WO2012098505A1 (fr) 2011-01-19 2012-07-26 Actelion Pharmaceuticals Ltd Dérivés de 2-methoxy-pyridin-4-yl

Also Published As

Publication number Publication date
DK2970236T3 (en) 2017-10-16
BR112015023161A8 (pt) 2021-06-22
HK1220454A1 (zh) 2017-05-05
EP2970236B1 (fr) 2017-08-30
SI2970236T1 (sl) 2017-11-30
EA029309B1 (ru) 2018-03-30
BR112015023161B1 (pt) 2022-11-16
US20160031866A1 (en) 2016-02-04
PT2970236T (pt) 2017-11-30
WO2014141171A1 (fr) 2014-09-18
KR20150128947A (ko) 2015-11-18
UA115357C2 (uk) 2017-10-25
HUE035154T2 (en) 2018-05-02
MX363545B (es) 2019-03-27
KR102212975B1 (ko) 2021-02-05
MX2015012293A (es) 2015-12-16
SA515361104B1 (ar) 2016-06-28
CL2015002620A1 (es) 2016-03-18
CA2900910C (fr) 2021-03-30
TWI623534B (zh) 2018-05-11
CN105189487B (zh) 2017-12-26
NO2970236T3 (fr) 2018-01-27
LT2970236T (lt) 2017-11-10
AU2014229217A1 (en) 2015-11-05
CY1119619T1 (el) 2018-04-04
JP2016512227A (ja) 2016-04-25
CA2900910A1 (fr) 2014-09-18
AR095523A1 (es) 2015-10-21
ZA201507657B (en) 2022-08-31
CN105189487A (zh) 2015-12-23
PH12015502118A1 (en) 2016-01-25
BR112015023161A2 (pt) 2017-07-18
EP2970236A1 (fr) 2016-01-20
ES2649475T3 (es) 2018-01-12
PL2970236T3 (pl) 2018-01-31
US9617250B2 (en) 2017-04-11
EA201500931A1 (ru) 2016-03-31
JP6387361B2 (ja) 2018-09-05
SG11201507227UA (en) 2015-10-29
TW201443044A (zh) 2014-11-16
PH12015502118B1 (en) 2016-01-25
MY173573A (en) 2020-02-04
NZ713080A (en) 2020-06-26
IL241363B (en) 2018-11-29
MA38482A1 (fr) 2017-12-29
AU2014229217B2 (en) 2017-12-14
HRP20171763T1 (hr) 2017-12-29
IL241363A0 (en) 2015-11-30

Similar Documents

Publication Publication Date Title
MA38482A1 (fr) Dérivés de pyridin-4-yle agonistes du recepteur de la sphingosine-1-phosphate utilises pour traiter, par ex. Syndromes auto-immuns, sclerose en plaques, colite ulcereuse, psoriasis et migraine
MA37959A2 (fr) Dérivés de 5-phénoxy-3h-pyrimidin-4-one et leur utilisation en tant qu'inhibiteurs de la transcriptase inverse du vih
EA201691070A1 (ru) Новые трициклические соединения в качестве противораковых средств
MA39898B1 (fr) Composés 4-amino-imidazoquinoline
MA39172A1 (fr) Dérivés bicycliques hétérocycliques comme inhibiteurs de bromodomaines
MA40111B1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
MA41562B1 (fr) Agonistes d'apj 4-hydroxy-3-(heteroaryl)pyridine-2-one a utiliser dans le traitement de troubles cardio-vasculaires
MA37866B1 (fr) Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur
MA42339A1 (fr) Modulateurs du récepteur farnésoïde x
MA47356A1 (fr) Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinases
MA46490A1 (fr) Dérivés de nucléosides 4'- fluoro-2' - méthyle substitués
MA43409B1 (fr) Composés polycycliques à utiliser en tant qu'inhibiteurs de la tyrosine kinase de bruton
MA35342B1 (fr) Composés de-pipéridinyle utiles comme inhibiteurs de la tankyrase
MA38645A1 (fr) Nouveaux inhibiteurs de cyp17/antiandrogènes
MA37439A1 (fr) Inhibiteurs de dgat1 à ponts éthers cycliques pour le traitement de troubles medies par l'acyle coa-diacylglycerol transferase 1 (dgat1).
MA35893B1 (fr) Dérivés d'amide hétérocyclique comme antagonistes du récepteur p2x7
MA38410A1 (fr) Composés d'azétidinyloxyphénylpyrrolidine
MA39165A1 (fr) Dérivés de benzimidazole-proline pour leurs utilisations dans le traitement du syndrome des etats crepusculaires
MA38679B1 (fr) Modulateurs du récepteur de cxcr7
MA43913B1 (fr) Modulateurs allostériques positifs du récepteur m1 muscarinique
MA34098B1 (fr) Utilisation de nouveaux inhibiteurs pan-cdk pour le traitement de tumeurs
MA39305A3 (fr) Dérivés d'éthynyle
MA38857B1 (fr) Dérivés de 1-(pipérazin-1-yl)-2-([1,2,4]triazol-1-yl)-éthanone
MX2016003725A (es) Compuestos y su uso para la preparacion de agentes de formacion de imagen tau y formulaciones para la formacion de imagen tau.
EA201691252A1 (ru) Соединения индазола в качестве агонистов 5-ht-рецептора